TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults 18-65 years of age~* Right-handed~* Controls: Not meet The Fourth Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for major depressive disorder (MDD) by scoring ≤7 on the Hamilton Depression Rating Scale (HDRS), 17-item; Treatment-Resistant Major Depression (TRMD) patients: Must meet a ≥17 score on the HDRS.~* Controls: Must not have any history of depression as determined by reported history and medical record review; TRMD: Documented (chart review) failure to respond to ≥3-4 adequate dose/duration antidepressant treatments; ≥1 in the current depressive episode.~* Good command of the English language~Exclusion Criteria:~* Meets criteria for any DSM-IV Axis I diagnosis as documented in medical records and as determined by structured clinical interview (except MDD for the TRMD group)~* Known primary neurological disorders or medical disorders including dementia, stroke, encephalopathy Parkinson's Disease, brain tumors, multiple sclerosis, seizure disorder, severe cardiac or pulmonary disease~* Any central nervous system active medication as determined by study investigator~* Any known disease affecting drug metabolism and excretion (e.g. renal or liver disease) as determined by study investigator~* Left-handedness~* Not eligible for MRI scans (e.g. history of claustrophobia/implanted metal as per MRI Screening Tool)~* Current use of psychotropic medications, antidepressants, or prescription or non-prescription drugs/herbals intended to treat depression or anxiety (control group only)~* Any recent (within past 12 months) history of substance dependence or abuse, determined by reported history or urine drug screen~* Ability to become pregnant and not using effective contraception~* Contraindication against the use of nitrous oxide:~  1. Pneumothorax~ 2. Bowel obstruction~ 3. Middle ear occlusion~ 4. Elevated intracranial pressure~ 5. Chronic cobalamin and/or folate deficiency treated with folic acid or vitamin B12~ 6. Pregnant patients~ 7. Breastfeeding women~* Inability to provide informed consent~* Any other factor that in the investigators' judgment may affect patient safety or compliance (e.g. distance greater than 100 miles from clinic).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Nitrous Oxide (Type: EXPERIMENTAL): One hour inhalation of nitrous oxide
- Placebo Gas (Type: PLACEBO_COMPARATOR): One hour inhalation of placebo gas

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ability of a Molecule (Prima) to Restore Physiological Differentiation in Epithelium Expressing Gene p63

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient with genetic pathology of the ocular surface~* Age ≥ 7 years~Exclusion Criteria:~* Agonal glaucoma~* low vision mostly related to retinal pathology~* Pregnant or breast-feeding patient

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Treatment of Burn Wounds With Antimicrobial Topical Soaks

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Burn Injury requiring excisional therapy~* Hospitalization required until wounds are closed~Exclusion Criteria:~* Known hypersensitivity to products~* Outpatient treatment for burn injury

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Sulfamylon 5% and Silver Nitrate Soaks (Type: EXPERIMENTAL): Application of Sulfamylon 5% Solution and Silver Nitrate soaked dressings to two different burned area. Sites were then monitored for infections during hospitalization.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Intensification of HIV-associated Non-Hodgkin's Lymphoma by Peripheral Blood Cell Transplantation Following Chemotherapy.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patients between 18 and 55 years old at screening~* Documented HIV-1 infection~* Currently HAART-treated~* Plasma HIV-RNA below 50 copies/ml at screening~* Lymphocyte T CD4+ count above or equal to 100/mm3 at the NHL diagnosis~* Histologically proven large cell NHL in first remission with classical poor prognostic factors (IPI above or equal to 2) or in second remission whatever IPI.~* Biological criteria of eligibility for intensive therapeutic~* Signed written informed consent~* Patient protected by the social security of one of the European community countries.~Exclusion Criteria:~* Burkitt NHL~* Central nervous system NHL~* Patients already treated by ASCT~* Ongoing infectious disease~* Psychiatric disease~* Left ventricular ejection fraction \< 25%~* Creatinine clearance \< 50 ml/min~* Hepatic failure~* Uncontrolled high blood pressure~* Chronic hepatitis C or B~* Participating in other trials.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Use of Light Therapy for Managing Sleep Disturbances in Patients With Advanced Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Advanced cancer patients seen in Supportive Care outpatient clinic at M.D. Anderson Cancer Center, with average sleep disturbance \>=4 out of 10 for at least one week~2. Age 18 or greater~3. Karnofsky performance status score of \>=40 at time of inclusion into study~4. Agrees to return to MD Anderson Cancer Center (MDACC) for follow-up visits~5. English speaking~Exclusion Criteria:~1. Persons with congenital blindness and self-reported acquired blindness (independent of the cause) with no light perception~2. Patients with a history of retinal disease~3. Patients with a current diagnosis of major depression disorder or generalized anxiety disorder~4. Patients who have received light therapy in the past either as part of treatment for other disorders or as a study subject~5. Patients currently on amiodarone, thiazide diuretics or epidermal growth factor receptor (EGFR) inhibitors (erlotinib, gefitinib, cetuximab, panitumumab)~6. Patients who are currently receiving ultraviolet A light/ultraviolet B light (UVA/UVB) therapy or tanning sessions at salons~7. Patients with a diagnosis of obstructive sleep apnea or narcolepsy~8. Patients with \>2 hours of direct exposure to outdoor natural light per day (light exposure diary -- screening).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bright Light Therapy (Type: EXPERIMENTAL): Daily Bright Light Therapy using Bright Light Litebook device for two 14 day periods.
- Dim Red Light Therapy (Type: PLACEBO_COMPARATOR): Daily Dim Red Light Therapy (placebo) using control Red Light Litebook device for 14 days then proceed to the open label phase and receive daily bright light for 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants (MK-0991-064)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Culture-confirmed invasive Candida infection~Exclusion Criteria:~* Candida disease limited to the oropharynx, esophagus, or other mucosal or superficial skin surfaces~* Positive culture for Candida only from sputum, broncho-alveolar lavage, catheter tip, or previously placed indwelling non-vascular catheters or drains~* Prosthetic device as the suspected site of Candida infection~* Active co-infection with a non-Candida fungal organism~* Received \>48 hours of systemic antifungal treatment since the positive Candida index culture was collected as therapy for the present episode of invasive candidiasis~* Failed prior systemic antifungal therapy for the present episode of invasive candidiasis~* Diagnosis of acute hepatitis or cirrhosis~* Scheduled or anticipated to receive rifampin or other systemic antifungal therapy while on study therapy~* History (including participant's mother) of allergy, hypersensitivity, or any serious reaction to caspofungin or other member of the echinocandin class, or to amphotericin B deoxycholate or other member of the polyene class~* Severe congenital disorder known to lower immune response

- Gender: ALL
- Minimum Age: None
- Maximum Age: 3 Months
- Healthy Volunteers: f

Study Arms:
- Caspofungin (Type: EXPERIMENTAL): Caspofungin 2 mg/kg intravenous once daily for ≥14 days after documented negative culture and improvement of clinical signs and symptoms, for a maximum of 90 days treatment
- Amphotericin B Deoxycholate (Type: ACTIVE_COMPARATOR): Amphotericin B deoxycholate 1 mg/kg intravenous once daily for ≥14 days after documented negative culture and improvement of clinical signs and symptoms, for a maximum of 90 days treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Adjuvant Post-Tamoxifen Exemestane Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* postmenopausal women only~* histologically confirmed stage I-IIIA primary adenocarcinoma of the breast~* estrogen and/or progesterone receptors positive or unknown~* patients should have undergone surgery with a curative intent~* patients must have completed at least 5 years and not more than 7 years of continued treatment with tamoxifen (20 mg/day), while tamoxifen could have been discontinued up to 6 months prior to study entry~* Absence of any evidence of local or distant metastatic disease was required prior to randomization~Exclusion Criteria:~* DCIS, bilateral breast cancer, evidence of metastasis, ER and Pgr negative

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1: observation only (Type: NO_INTERVENTION): Patients have completed at least 5 years and not more than 7 years of continued treatment with tamoxifen (20 mg/day). Tamoxifen could have been discontinued up to 6 months prior to study entry.
- 2: Exemestane (Type: ACTIVE_COMPARATOR): Patients randomised to receive exemestane (25 mg/day) for 5 years, following completion of 5-7 years of Tamoxifen treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed adenocarcinoma of the pancreas~* Prior failed 1st line gemcitabine therapy for metastatic disease or relapsed within six months of completion of gemcitabine adjuvant therapy~* Prior capecitabine or 5fu is allowed in the setting of radiation~* Must either be able to swallow or receive enteral nutrition via gastrostomy feeding tube~* Cardiac ejection fraction within institutional range of normal as measured by echocardiogram~* ECOG performance status 0-2~* Signed informed consent form~* Adequate hepatic, bone marrow, and renal function~Exclusion Criteria:~* Any prior treatment with lapatinib, or any anti-HER2 treatment or any anti-EGFR treatment~* Not recovered from adverse events to a toxicity grade \</= 1 due to prior chemotherapy~* More than one prior chemotherapy regimens~* Known brain metastases, uncontrolled seizure disorders, encephalitis, or multiple sclerosis~* HIV positive on antiretroviral therapy~* Pregnant or lactating~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinib or capecitabine~* Malabsorption syndrome or uncontrolled inflammatory GI disease (Crohn's or ulcerative colitis)~* Known history of uncontrolled or symptomatic angina, arrhythmia, or congestive heart failure~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/ social situations that would limit compliance with study requirements~* Known dihydropyrimidine dehydrogenase deficiency~* Concurrent malignancy unless the subject has been curatively treated and disease free for \>/= 2 years or the cancer was non-melanoma skin cancer or early cervical cancer.~* Creatinine clearance \< 30 mL/min~* Absolute neutrophil count \< 1500, platelets \< 75,000~* Transaminases \> 3.0 times the upper limit of normal, except in known hepatic metastasis, wherein they must be \< 5.0 times the upper limit of normal~* Total bilirubin \> 1.5 times the ULN, \> 2.5 x ULN if patient has Gilbert's syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lapatinib and Capecitabine (Type: EXPERIMENTAL): Treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of primary gastrointestinal and/or retroperitoneal sarcoma~* Scheduled to undergo ≥ 3000 cGy or ≥ 3 weeks of external beam radiation to the abdomen~  * Radiotherapy fields to extend between T11 and L3, and of a size ≥ 100 cm\^2~* No brain metastases~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Negative pregnancy test~* Not pregnant or nursing~* Fertile patients must use effective contraception~* Able to complete questionnaire(s) alone or with assistance~* Willing to return to NCCTG enrolling institution for follow-up~* Able to reliably take oral medication (for purposes of rescue medication)~* No hypersensitivity to palonosetron hydrochloride or other selective 5-HT3 receptor antagonists~* No comorbid systemic illness or other severe concurrent disease that, in the judgment of the investigator, would make the patient inappropriate for study entry or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens~* No nausea ≤ 48 hours prior to study enrollment~* No history of dystonic reactions to prochlorperazine or haloperidol or related agents~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* More than 7 days since prior agents known to have significant effects on emesis, including the following:~  * Ondansetron~ * Sedating antihistamines~ * Antipsychotics~ * Cannabinoids~ * Corticosteroids~ * Metoclopramide~ * Narcotic analgesics~ * Benzodiazepines~* More than 7 days since prior chemotherapy other than fluorouracil or capecitabine used as a radiosensitizer~* More than 7 days since of prior cetuximab~* More than 7 days since prior and no concurrent oral steroids~* No prior palonosetron hydrochloride

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive palonosetron hydrochloride IV on day 1.
- Arm II (Type: EXPERIMENTAL): Patients receive palonosetron hydrochloride IV on days 1 and 4.
- Arm III (Type: PLACEBO_COMPARATOR): Patients receive placebo IV on day 1.
- Arm IV (Type: PLACEBO_COMPARATOR): Patients receive placebo IV on days 1 and 4.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of cNEP for the Treatment of Snoring

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* sleep test within the previous six months that shows snoring of at least 30 dB for at least 30% of total sleep time~* AHI \< 10/hr~Exclusion Criteria:~* previous neck surgery or radiation~* carotid artery disease~* serious medical or psychiatric illness~* pregnancy~* silicone allergy~* excessive use of alcohol or sedating drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- treatment (Type: EXPERIMENTAL): continuous negative external pressure (cNEP) at various negative pressures

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Nosocomial Infections During Total Prostatic Cystectomies (TPC) With Replacement Enterocystoplasty: Prophylactic Role of Urell®, Cranberry Fruit Juice Extract (Vaccicium Macrocarpon)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patient aged \> 18 years old~* patient with bladder cancer and total prostatic cystectomy with replacement enterocystoplasty~* signed informed consent~* patient with healthcare insurance~Exclusion Criteria:~* patient without signed informed consent~* patient deprived of liberty by judicial or administrative decision

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prophylactic efficacy of Urell® (Type: EXPERIMENTAL): Prophylactic efficacy of Urell® on urinary tract infections in patients with bladder cancer and total prostatic cystectomy with replacement enterocystoplasty

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess CLn® BodyWash for Reducing Skin Fauna in Patients With Hand Eczema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Seen by an OSU Dermatology provider at OSU Dermatology East after the date of approval of this protocol~* Ability to provide informed consent, or parent or legal guardian capable of providing consent for child or mentally handicapped individuals~* Willingness to participate in a research study.~* Diagnosis of chronic hand dermatitis~Exclusion Criteria:~* Inability to provide informed consent~* Allergy to any of the treatments used

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CLn BodyWash (Type: ACTIVE_COMPARATOR): CLn BodyWash will be used to wash hands of patients with Hand Atopic Dermatitis
- Cetaphil Daily Facial Cleanser (Type: ACTIVE_COMPARATOR): Cetaphil Daily Facial Cleanser will be used to wash hands of patients with Hand Atopic Dermatitis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Be at least 18 years of age~* Have end stage renal disease (ESRD) and is receiving a kidney transplant from a living donor to whom he/she has a baseline anti-blood group titer \>1:32~* Be vaccinated against N. meningitides (quadrivalent vaccine), H. Flu, and pneumococcal disease at least two weeks prior to beginning desensitization.~Exclusion Criteria:~* Has an unstable cardiovascular condition~* Has had a previous splenectomy~* Has any active bacterial or other infection~* Has a known or suspected hereditary complement deficiency~* Has known hypersensitivity to the treatment drug or any of its excipients~* Has history of illicit drug use or alcohol abuse within the previous year~* Has history of meningococcal disease~* Has any medical condition that, in the opinion of the investigator, might interfere with the patient's participation in the study, pose an added risk for the patient, or confound the assessment of the patient (e.g. severe cardiovascular or pulmonary disease)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- eculizumab (Type: EXPERIMENTAL): Eculizumab was given on Day 0, day 1, and weekly for the first four weeks after transplant.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues